Did they ever move into the second cohort? I think it would be beneficial to see the outcome differences between dosing levels (or maybe no anticipated differences due to half life?).
One can give all the twist to this but the fact remains that K is thrown under the bus.
If the results were so good - K would have moved much faster - it is clearly in back burner and may not even be mentioned in the next 10-q
K was Menon’s baby and his salary cut and his appearance from any company PR shows that K is not a key component
Rather than abandoning K in A single PR and raising concerns - he is taking slow approach - he clarified in PR today that you will hear about K till oral formulation is done and it is not a given. So no one can ask questions.
Remember gram negative compound and fox chase work - how it was dropped and then IP was given back?
You can say trial was not a failure - maybe. However as someone said this is the case of “ “ “OPERATION SUCCESSFUL PATIENT DIED”
Wrong again. A trial discontinued by the company can’t meet the primary endpoints. I guarantee you Uncle Leo will never claim the K trial met the primary endpoints.
The real insult to injury here is that Menon gave away millions of shares to Aruda for a compound that is worth nothing. And he did this privately without making Aspire prove anything. And Leo the great businessman signed off.
Market Data 
Markets 
AI
